Minghe Luo | Natural Products Biosynthesis | Editorial Board Member

Published on by Biotechnology Scientist

Assoc. Prof. Dr. Minghe Luo | Natural Products Biosynthesis | Editorial Board Member

Associate Professor at Chongqing University of Technology | China

Assoc. Prof. Dr. Minghe Luo is a highly accomplished researcher specializing in natural products chemistry, microbial biosynthesis, medicinal chemistry, and marine-derived bioactive compounds, with a strong scientific record demonstrated by 826 citations, 36 peer-reviewed publications, and an h-index of 18 on Scopus. His research integrates natural product discovery, biosynthetic pathway elucidation, enzymatic function analysis, and bioactivity evaluation, contributing significantly to the development of antibacterial agents, hepatoprotective molecules, siderophores, diketopiperazines, and structurally diverse marine fungal metabolites. Dr. Luo has made major advancements in understanding complex biosynthetic mechanisms, including cytochrome P450–mediated oxidation, polyketide assembly, and enzyme-catalyzed tailoring reactions, highlighted in high-impact journals such as Angewandte Chemie International Edition, Nature Communications, Chemical Engineering Journal, Journal of Natural Products, and Organic Letters. His work also includes innovative studies on deep-sea fungi, Streptomyces species, and marine actinomycetes, leading to the discovery of new anthraquinones, nucleoside antibiotics, and novel polyketide derivatives. As both first author and corresponding author on multiple publications, Dr. Luo has demonstrated strong scientific leadership, editorial judgment, and expertise in guiding research from discovery to mechanistic analysis. He has contributed to several nationally funded research projects and has led investigations into antibacterial natural products and biosynthetic gene clusters, reinforcing his role as an influential scientist in pharmaceutical biotechnology. Dr. Luo’s extensive publication record, multidisciplinary expertise, and consistent scientific impact make him exceptionally well-suited for an Editorial Board Member role in journals focused on natural products, biosynthesis, pharmaceutical chemistry, and microbial biotechnology.

Profiles : Scopus | ORCID | Google Scholar

Featured Publications

Ma, J., Wang, Z., Huang, H., Luo, M., Zuo, D., Wang, B., Sun, A., Cheng, Y. Q., & Ju, J. (2011). Biosynthesis of himastatin: Assembly line and characterization of three cytochrome P450 enzymes involved in the post-tailoring oxidative steps. Angewandte Chemie International Edition. (Cited by: 103)

Shi, S., Zhou, M., Li, X., Hu, M., Li, C., Li, M., Sheng, F., Li, Z., Wu, G., Luo, M., Cui, H., & others. (2016). Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. Journal of Controlled Release. (Cited by: 92)

Huang, H., Wang, F., Luo, M., Chen, Y., Song, Y., Zhang, W., Zhang, S., & Ju, J. (2012). Halogenated anthraquinones from the marine-derived fungus Aspergillus sp. SCSIO F063. Journal of Natural Products. (Cited by: 88)

Li, Y., Shi, S., Ming, Y., Wang, L., Li, C., Luo, M., Li, Z., Li, B., & Chen, J. (2018). Specific cancer stem cell therapy by albumin nanoparticles functionalized with CD44-mediated targeting. Journal of Nanobiotechnology. (Cited by: 72)

Ming, Y., Li, Y., Xing, H., Luo, M., Li, Z., Chen, J., Mo, J., & Shi, S. (2017). Circulating tumor cells: From theory to nanotechnology-based detection. Frontiers in Pharmacology. (Cited by: 66)

 

Xiaojiang Qin | Natural Products Chemistry‌ | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Xiaojiang Qin | Natural Products Chemistry‌ | Best Researcher Award

Professor at Shanxi Medical University, China

Dr. Qin Xiaojiang is a distinguished professor and doctoral supervisor at Shanxi Medical University, China, where he also serves as the Associate Director of the Department of Science and Technology. With extensive experience in academic leadership and scientific research, he has made a profound impact in the fields of vascular toxicology, environmental exposure, and natural product pharmacology. Dr. Qin also directs the Institute of Environmental Exposure and Vascular Diseases and plays a pivotal role in guiding the Shanxi Provincial Science & Technology Innovation Team. His academic endeavors and leadership contributions have established him as a key figure in medical science research both nationally and internationally.

Profile

Orcid

Scopus

Education

Dr. Qin earned his Ph.D. in Medicine from Shanxi Medical University, where he built a strong foundation in clinical and translational medical research. Further advancing his global academic footprint, he completed a prestigious visiting scholar program at the University of California, San Francisco (UCSF) between 2019 and 2020. His international training enriched his scientific perspective and fostered interdisciplinary collaborations, especially in environmental health and vascular biology.

Experience

Over the years, Dr. Qin has accumulated a wealth of experience in both academic and administrative roles. As the Associate Director of the Department of Science and Technology at Shanxi Medical University, he has overseen various high-impact research initiatives and institutional advancements. He also leads the Institute of Environmental Exposure and Vascular Diseases, where his team conducts pioneering research on the vascular impacts of environmental pollutants. His leadership extends to regional innovation efforts, guiding the Shanxi Provincial Science & Technology Innovation Team in advancing biomedical discoveries.

Research Interest

Dr. Qin’s research primarily explores the pathogenic mechanisms of vascular toxicity resulting from environmental exposures, including tobacco-related and industrial pollutants. He is also deeply involved in the development of population-level tobacco control strategies to mitigate public health risks. Another cornerstone of his research lies in drug discovery derived from bioactive natural products, with the goal of identifying novel therapeutic agents with minimal adverse effects. His interdisciplinary approach bridges molecular toxicology, epidemiology, and pharmacognosy.

Award

Dr. Qin’s scientific excellence has been acknowledged through various grants and leadership recognitions. He has successfully secured three prestigious National Natural Science Foundation of China (NSFC) grants as Principal Investigator, affirming the national importance of his research. Additionally, he has led or co-led more than a dozen provincial, ministerial, and industry-sponsored research projects, underlining his capability in driving innovation and collaborative research in the life sciences.

Publication

Dr. Qin has published extensively, with 69 peer-reviewed articles in SCI/EI-indexed and core journals. His publications reflect his depth of inquiry into toxicological mechanisms and therapeutic discoveries. Select publications include:

  1. Toxicology and Applied Pharmacology (2018) – cited by 42 articles.

  2. Biomedicine & Pharmacotherapy (2019) – cited by 36 articles.

  3. Environmental Research (2020) – cited by 28 articles.

  4. Journal of Ethnopharmacology (2021) – cited by 25 articles.

  5. Frontiers in Pharmacology (2022) – cited by 21 articles.

  6. Scientific Reports (2020) – cited by 19 articles.

  7. International Journal of Molecular Sciences (2023) – cited by 15 articles.
    In addition to research papers, he holds two authorized invention patents and ten utility model patents, showcasing his innovation in translational research and applied technologies.

Conclusion

In conclusion, Dr. Qin Xiaojiang embodies the values of excellence in academic research, innovation, and scientific leadership. His deep commitment to understanding and combating vascular diseases through environmental toxicology and natural product pharmacology has yielded important scientific insights and public health applications. With a robust publication record, international research exposure, and multiple prestigious project leaderships, he stands as an exemplary candidate for any recognition in scientific achievement. His work not only advances medical science but also contributes meaningfully to community health and technological progress.